{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:34:31Z","timestamp":1789497271943,"version":"build-2803163510"},"reference-count":92,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Methotrexate (MTX), a structurally related substance to folic acid, is an important chemotherapeutic agent used for decades in the treatment of pediatric acute lymphoblastic leukemia (ALL) and other types of cancer as non-Hodgkin lymphomas and osteosarcomas. Despite the successful outcomes observed, the primary drawback is the variability in the pharmacokinetics and pharmacodynamics between patients. The main adverse events related to its use are nephrotoxicity, mucositis, and myelosuppression, especially when used in high doses. The potential adverse reactions and toxicities associated with MTX are a cause for concern and may lead to dose reduction or treatment interruption. Genetic variants in MTX transport genes have been linked to toxicity. Pharmacogenetic studies conducted in the past focused on single nucleotide polymorphisms (SNPs) in the coding and 5\u2032-regulatory regions of genes. Recent studies have demonstrated a significant role of microRNAs (miRNAs) in the transport and metabolism of drugs and in the regulation of target genes. In the last few years, the number of annotated miRNAs has continually risen, in addition to the studies of miRNA polymorphisms and MTX toxicity. Therefore, the objective of the present study is to investigate the role of miRNA variants related to MTX adverse effects.<\/jats:p>","DOI":"10.3390\/hematolrep15040065","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T01:54:12Z","timestamp":1700445252000},"page":"634-650","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Association of microRNA Polymorphisms with Toxicities Induced by Methotrexate in Children with Acute Lymphoblastic Leukemia"],"prefix":"10.3390","volume":"15","author":[{"given":"Vasiliki","family":"Karpa","sequence":"first","affiliation":[{"name":"Laboratory of Medical Biology-Genetics, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kallirhoe","family":"Kalinderi","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Biology-Genetics, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Fidani","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Biology-Genetics, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4294-2605","authenticated-orcid":false,"given":"Athanasios","family":"Tragiannidis","sequence":"additional","affiliation":[{"name":"Pediatric & Adolescent Hematology-Oncology Unit, 2nd Pediatric Department, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital, S. Kiriakidi 1, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-020-00170-6","article-title":"Leukemia incidence trends at the global, regional, and national level between 1990 and 2017","volume":"9","author":"Dong","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/1389200220666190130161758","article-title":"Clinical Implications of Methotrexate Pharmacogenetics in Childhood Acute Lymphoblastic Leukaemia","volume":"20","author":"Gervasini","year":"2019","journal-title":"Curr. Drug Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/FPC.0000000000000245","article-title":"MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia","volume":"26","author":"Iparraguirre","year":"2016","journal-title":"Pharmacogenetics Genom."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-013-1623-4","article-title":"Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: Why still at the bench level?","volume":"70","author":"Kodidela","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2165\/00003088-200645120-00007","article-title":"Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia","volume":"45","author":"Aumente","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.gpb.2016.11.003","article-title":"The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment","volume":"15","author":"Rudin","year":"2017","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.paed.2015.10.007","article-title":"Childhood leukaemia: An update","volume":"26","author":"Vora","year":"2016","journal-title":"Paediatr. Child Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejps.2017.09.006","article-title":"Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases","volume":"109","author":"Giletti","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_9","first-page":"e8674","article-title":"High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Predictors of Delayed Clearance and the Effect of Increased Hydration Rate on Methotrexate Clearance","volume":"12","author":"Chen","year":"2020","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3109\/10428194.2011.639880","article-title":"Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia","volume":"53","author":"Kotnik","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Liu, Y., Yin, Y., Sheng, Q., Lu, X., Wang, F., Lin, Z., Tian, H., Xu, A., and Zhang, J. (2014). Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS ONE, 9, Erratum in PLoS ONE 2014, 9, e91384.","DOI":"10.1371\/journal.pone.0091384"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s12032-011-9997-6","article-title":"Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia","volume":"29","author":"Eid","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Hua, Z., Luo, X., Li, Y., Yu, L., Li, M., Lu, C., Zhao, T., and Liu, Y. (2022). Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomed. Pharmacother., 150.","DOI":"10.1016\/j.biopha.2022.113074"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-015-0158-9","article-title":"Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia","volume":"8","author":"Wojtuszkiewicz","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.20181965","article-title":"Toward a better understanding of folate metabolism in health and disease","volume":"216","author":"Zheng","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0083-6729(08)00405-6","article-title":"Structure and function of the reduced folate carrier a paradigm of a major facilitator superfamily mammalian nutrient transporter","volume":"79","author":"Matherly","year":"2008","journal-title":"Vitam. Horm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0162-3109(00)00189-2","article-title":"Mechanisms of action of methotrexate","volume":"47","author":"Genestier","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI112088","article-title":"Polyglutamation of methotrexate. Is methotrexate a prodrug?","volume":"76","author":"Chabner","year":"1985","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1003812","DOI":"10.3389\/fphar.2022.1003812","article-title":"Association between high-dose methotrexate-induced toxicity and polymorphisms within methotrexate pathway genes in acute lymphoblastic leukemia","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s12288-019-01245-z","article-title":"Adverse effects with intravenous methotrexate in children with acute lymphoblastic leukemia\/lymphoma: A retrospective study","volume":"36","author":"Mandal","year":"2020","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1002\/onco.13603","article-title":"Standardized Supportive Care Documentation Improves Safety of High-Dose Methotrexate Treatment","volume":"26","author":"Alsdorf","year":"2021","journal-title":"Oncologist"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and Managing Toxicities of High-Dose Methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1007\/s00520-021-06106-y","article-title":"Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate","volume":"29","author":"Barreto","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1517\/14622416.5.7.819","article-title":"Pharmacogenetics of methotrexate","volume":"5","author":"Krajinovic","year":"2004","journal-title":"Pharmacogenomics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41397-018-0047-z","article-title":"Genetic markers in methotrexate treatments","volume":"18","author":"Giletti","year":"2018","journal-title":"Pharmacogenom. J."},{"key":"ref_26","unstructured":"Leclerc, D., Sibani, S., and Rozen, R. (2023, September 10). Molecular Biology of Methylenetetrahydrofolate Reductase (MTHFR) and Overview of Mutations\/Polymorphisms, Madame Curie Bioscience Database [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK6561\/."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.leukres.2007.03.028","article-title":"MTHFR polymorphisms\u2019 influence on outcome and toxicity in acute lymphoblastic leukemia patients","volume":"31","author":"Chiusolo","year":"2007","journal-title":"Leuk. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2217\/pgs.14.106","article-title":"Pharmacogenetics of childhood acute lymphoblastic leukemia","volume":"15","year":"2014","journal-title":"Pharmacogenomics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00277-007-0274-x","article-title":"Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia","volume":"86","author":"Pakakasama","year":"2007","journal-title":"Ann. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/tpj.2012.44","article-title":"A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia","volume":"13","author":"Ballesteros","year":"2013","journal-title":"Pharmacogenom. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","article-title":"Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma","volume":"67","author":"Grabnar","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/j.1745-7254.2007.00643.x","article-title":"Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients","volume":"28","author":"Xu","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/bcp.13207","article-title":"Interindividual and interethnic variability in drug disposition: Polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1)","volume":"83","author":"Lee","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156","article-title":"Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects","volume":"27","author":"Shimasaki","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/pbc.23074","article-title":"Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia","volume":"57","author":"Ballesteros","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1182\/blood-2013-01-480335","article-title":"Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia","volume":"121","author":"Radtke","year":"2013","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","article-title":"Genome-wide study of methotrexate clearance replicates SLCO1B1","volume":"121","author":"Ramsey","year":"2013","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00393-018-0419-4","article-title":"TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis. TYMS-Polymorphismen und Empfindlichkeit gegen\u00fcber oder Toxizit\u00e4t von Methotrexat bei rheumatoider Arthritis","volume":"77","author":"Bae","year":"2018","journal-title":"Z. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.leukres.2008.12.006","article-title":"Polymorphisms of xenobiotic metabolizing enzymes and DNA repair genes and outcome in childhood acute lymphoblastic leukemia","volume":"33","author":"Canalle","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(02)08065-0","article-title":"Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia","volume":"359","author":"Krajinovic","year":"2002","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/sj.tpj.6500332","article-title":"Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis","volume":"5","author":"Krajinovic","year":"2005","journal-title":"Pharmacogenom. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1182\/blood-2004-11-4544","article-title":"Pharmacogenetics of outcome in children with acute lymphoblastic leukemia","volume":"105","author":"Rocha","year":"2005","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/pbc.23192","article-title":"Germline genetic variation and treatment response on CCG-1891","volume":"58","author":"Sepe","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/FPC.0000000000000069","article-title":"Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia","volume":"24","author":"Zgheib","year":"2014","journal-title":"Pharmacogenet. Genom."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fped.2020.00307","article-title":"Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate","volume":"8","author":"Cwiklinska","year":"2020","journal-title":"Front. Pediatr."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Kotur, N., Lazic, J., Ristivojevic, B., Stankovic, B., Gasic, V., Dokmanovic, L., Krstovski, N., Milosevic, G., Janic, D., and Zukic, B. (2020). Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment. Genes, 11.","DOI":"10.3390\/genes11040468"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bbacli.2015.01.006","article-title":"Cancer metabolism and oxidative stress: Insights into carcinogenesis and chemotherapy via the non-dihydrofolate reductase effects of methotrexate","volume":"3","author":"Hess","year":"2015","journal-title":"BBA Clin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1158\/1078-0432.CCR-09-0641","article-title":"DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia","volume":"15","author":"Dulucq","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2007-09-110593","article-title":"DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL","volume":"111","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3892\/etm.2012.447","article-title":"Survival and risk of relapse of acute lymphoblastic leukemia in a Mexican population is affected by dihydrofolate reductase gene polymorphisms","volume":"3","year":"2012","journal-title":"Exp. Ther. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.arcmed.2019.07.010","article-title":"Association Between the 5,10-MTHFR 677C>T and RFC1 80G>A Polymorphisms and Acute Lymphoblastic Leukemia","volume":"50","year":"2019","journal-title":"Arch. Med. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hon.965","article-title":"Xenobiotic and folate pathway gene polymorphisms and risk of childhood acute lymphoblastic leukaemia in Javanese children","volume":"29","author":"Chan","year":"2011","journal-title":"Hematol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2008-07-165928","article-title":"Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia","volume":"113","author":"Tissing","year":"2009","journal-title":"Blood"},{"key":"ref_55","first-page":"446","article-title":"Association of single nucleotide polymorphism of reduced folate carrier gene with susceptibility to acute leukemia","volume":"28","author":"Zhao","year":"2011","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"key":"ref_56","first-page":"52","article-title":"Association Between RFC1 G80A Polymorphism and Acute Lymphoblastic Leukemia: A Review and Meta-Analysis of 10 Studies","volume":"6","author":"Salehi","year":"2016","journal-title":"Iran. J. Pediatr. Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1515\/raon-2017-0040","article-title":"Association between SLC19A1 Gene Polymorphism and High Dose Methotrexate Toxicity in Childhood Acute Lymphoblastic Leukaemia and Non Hodgkin Malignant Lymphoma: Introducing a Haplotype based Approach","volume":"51","author":"Kotnik","year":"2017","journal-title":"Radiol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1182\/blood-2010-01-256958","article-title":"The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number","volume":"115","author":"Gregers","year":"2010","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/blood-2006-10-054528","article-title":"Ancestry and pharmacogenetics of antileukemic drug toxicity","volume":"109","author":"Kishi","year":"2007","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00280-011-1751-4","article-title":"The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue","volume":"69","author":"Chiusolo","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3109\/10428194.2014.898761","article-title":"Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: A meta-analysis","volume":"55","author":"He","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_62","first-page":"2903","article-title":"The functional role of microRNA in acute lymphoblastic leukemia: Relevance for diagnosis, differential diagnosis, prognosis, and therapy","volume":"8","author":"Luan","year":"2015","journal-title":"Onco Targets Ther."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Mendiola-Soto, D.K., B\u00e1rcenas-L\u00f3pez, D.A., P\u00e9rez-Amado, C.J., Cruz-Miranda, G.M., Mej\u00eda-Arangur\u00e9, J.M., Ram\u00edrez-Bello, J., Hidalgo-Miranda, A., and Jim\u00e9nez-Morales, S. (2023). miRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065436"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.3390\/ijms16048110","article-title":"Sequence features of Drosha and Dicer cleavage sites affect the complexity of isomiRs","volume":"16","author":"Witkos","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1153767","DOI":"10.3389\/fped.2023.1153767","article-title":"Impact of microRNA polymorphisms on high-dose methotrexate-related hematological toxicities in pediatric acute lymphoblastic leukemia","volume":"11","author":"Zhan","year":"2023","journal-title":"Front. Pediatr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3389\/fgene.2019.00933","article-title":"Comprehensive Analysis of Human microRNA-mRNA Interactome","volume":"10","author":"Plotnikova","year":"2019","journal-title":"Front. Genet."},{"key":"ref_67","first-page":"161","article-title":"The Role of MicroRNAs in Human Diseases","volume":"2","author":"Ardekani","year":"2010","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Condrat, C.E., Thompson, D.C., Barbu, M.G., Bugnar, O.L., Boboc, A., Cretoiu, D., Suciu, N., Cretoiu, S.M., and Voinea, S.C. (2020). miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells, 9.","DOI":"10.3390\/cells9020276"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.3390\/ijms14035519","article-title":"MicroRNAs in Human Placental Development and Pregnancy Complications","volume":"14","author":"Fu","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.cell.2012.02.005","article-title":"MicroRNAs in stress signaling and human disease","volume":"148","author":"Mendell","year":"2012","journal-title":"Cell"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Correia, N.C., and Barata, J.T. (2019). MicroRNAs and their involvement in T-ALL: A brief overview. Adv. Biol. Regul., 74.","DOI":"10.1016\/j.jbior.2019.100650"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"15114","DOI":"10.1038\/ncomms15114","article-title":"Genetic variation and RNA structure regulate microRNA biogenesis","volume":"8","author":"Fernandez","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.med.59.053006.104707","article-title":"MicroRNAs in Cancer","volume":"60","author":"Garzon","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"re3","DOI":"10.1126\/scisignal.2005825","article-title":"Dysregulation of microRNA biogenesis and gene silencing in cancer","volume":"8","author":"Hata","year":"2015","journal-title":"Sci. Signal."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ncb0309-228","article-title":"Many roads to maturity: MicroRNA biogenesis pathways and their regulation","volume":"11","author":"Winter","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7901","DOI":"10.1038\/s41598-017-08148-x","article-title":"Comprehensive miRNA expression profiling in human T-cell acute lymphoblastic leukemia by small RNA-sequencing","volume":"7","author":"Wallaert","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/emmm.201100209","article-title":"MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review","volume":"4","author":"Iorio","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2141.2008.07077.x","article-title":"Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma","volume":"141","author":"Lawrie","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1002\/jcb.26800","article-title":"MicroRNA-326 and microRNA-200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia","volume":"119","author":"Ghodousi","year":"2018","journal-title":"J. Cell Biochem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"8941471","DOI":"10.1155\/2019\/8941471","article-title":"The Role of MicroRNA in Paediatric Acute Lymphoblastic Leukaemia: Challenges for Diagnosis and Therapy","volume":"2019","author":"Grobbelaar","year":"2019","journal-title":"J. Oncol."},{"key":"ref_81","first-page":"e9238","article-title":"Relapsed Childhood Acute Lymphoblastic Leukemia: A Single-Institution Experience","volume":"12","author":"Tuong","year":"2020","journal-title":"Cureus"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1093\/hmg\/ddr428","article-title":"A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL","volume":"20","author":"Han","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3324\/haematol.2010.026138","article-title":"MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia","volume":"96","author":"Schotte","year":"2011","journal-title":"Haematologica"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0000000000000291","article-title":"The miR-1206 microRNA variant is associated with methotrexate-induced oral mucositis in pediatric acute lymphoblastic leukemia","volume":"27","author":"Oosterom","year":"2017","journal-title":"Pharmacogenetics Genom."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.2217\/pgs-2017-0164","article-title":"Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment","volume":"19","author":"Umerez","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/epi-2017-0138","article-title":"Pharmacoepigenetics in childhood acute lymphoblastic leukemia: Involvement of miRNA polymorphisms in hepatotoxicity","volume":"10","author":"Umerez","year":"2018","journal-title":"Epigenomics"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"da Silva Menezes, E., de Moraes, F.C.A., de Nazar\u00e9 Cohen-Paes, A., Wanderley, A.V., Pereira, E.E.B., Pastana, L.F., Modesto, A.A.C., de Assump\u00e7\u00e3o, P.P., Burbano, R.M.R., and Dos Santos, S.E.B. (2023). Influence of Genetic Variations in miRNA and Genes Encoding Proteins in the miRNA Synthesis Complex on Toxicity of the Treatment of Pediatric B-Cell ALL in the Brazilian Amazon. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054431"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.blre.2015.01.001","article-title":"Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy","volume":"29","author":"Mei","year":"2015","journal-title":"Blood Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.leukres.2018.01.004","article-title":"Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia","volume":"65","author":"Wang","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jgm.2990","article-title":"Association between MTHFR microRNA binding site polymorphisms and methotrexate concentrations in Chinese pediatric patients with acute lymphoblastic leukemia","volume":"19","author":"Wang","year":"2017","journal-title":"J. Gene Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1073\/pnas.0706217104","article-title":"A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance","volume":"104","author":"Mishra","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-L\u00f3pez, E., Guti\u00e9rrez-Camino, \u00c1., Pi\u00f1\u00e1n, M.\u00c1., S\u00e1nchez-Toledo, J., Uriz, J.J., Ballesteros, J., Garc\u00eda-Miguel, P., Navajas, A., and Garc\u00eda-Orad, \u00c1. (2014). Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0091261"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/4\/65\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:25:53Z","timestamp":1760131553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/15\/4\/65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":92,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["hematolrep15040065"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep15040065","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]}}}